VIROSOMES: A NOVEL VESICULAR DRUG DELIVERY

Harsha Upadhye, Shreya Devmane, Radhika Subhedar, Sardar Shelake, Dr.N.B Chougule

Ashokrao Mane Institute of Pharmacy Ambap, Kolhapur

ABSTRACT : Virosomes are targeted drug delivery system. These cells or tissues can receive macromolecules by cellular administration, Virosomes are biomimetic nanoparticles drug delivery system, where active macromolecule packed into viral coat which are made by lipoidal membrane. mostly utilized for gene, nucleic acid, and protein delivery, Virosomes an essentially vacuous viruses' wrappers that have been reassembled. Because they lack genetic material, they cannot proliferate like the initial harmful infection. The purified viral envelope components are combined with additional endogenous lipids, such as cholesterol and phospholipids. Drugs can be modified by changing their chemical or physical properties, which can lead to the synthesis of new compounds, by mixing the medication with other substances to change how it releases its ingredients in vivo, or by changing the physical structures of the drug molecules. More significantly, targeting molecules (like antibodies) can be coupled to this Hydrophilic polymer and introduced into virosome membranes to produce a target selection capability. virosomes have demonstrated significant potential in delivering anticancer drugs, achieving controlled release and improved bioavailability. Additionally, their application in vaccine delivery has shown promise, with virosomes effectively inducing robust immune responses without the risks associated with live attenuated viruses. virosomes represent a transformative approach in the field of drug delivery, combining the precision of viral vectors with the safety profile of non-viral systems. Continued research and development in this area are essential to fully realize their potential and translate these findings into clinical practice, potentially revolutionizing the treatment landscape for various diseases.

Keywords: Virosomes, Target drug delivery system, Therapeutic agent, Biodegradable,

Introduction

A macromolecular drug administration or carrier method, virosomes are made of phospholipid membranes with protein generated from viruses that enable the virosomes to merge with the intended cell. Targeted cells or tissues can receive macromolecules by cellular administration. mostly utilized for gene, nucleic acid, and protein delivery. Steroids, antibiotics, and anticancer

agents are also given to thespecific cell. Virosomes are autoimmune, biodegradable, non-toxic, or permeable by nature. [1]

Reconstituted viral membranes known as virosomes are created by extracting nucleocapsids from enveloped viruses, which contain therapeutic components such as proteins, nuclear acids, and medicines in their core cavity. They resemble the natural virus they are derived from morphologically. Almedia et al. reported the first use of virosomes in 1975, when they used premade liposomes to transfer pure influenza spike proteins. Viral envelopes have since been regenerated using a variety of encapsulated viruses. [2]

A variety of enveloped viruses, such as the influenza, vesicle stomatitis, Newcastle disease, and Sendai viruses, have been investigated with the fundamental general concept of restoration of empty viral envelopes. In addition to being discovered to be effective as vaccinations vs the host virus, virosomes were also used as delivery methods for medicines, nucleic acids, as well as distinct vaccine antigens. Based on the influenza virus's envelope proteins, immunopotentiating restored influenza virosomes (IRIVs) are the most sophisticated virosomal platforms for targeted delivery or releasing. [3]

Virosomes become new envelopes of the influenza virus. Anywhere infected neuclocapside is present, substitute a preferred molecule. Since virosomes are pure fusion activity vesicles and cannot multiply, they transfer integrated compounds such as drugs, antigens that are or genes—into the desired body. When pharmaceutically active compounds enter the cytoplasm, their contents are preserved because virosomes shield them from endosomes' low pH and proteolytic destruction. More recently discovered drug delivery methods than liposomal and proteo liposomal carrier systems are found in the virosome carrier system. [4]

Definition

Drug molecules, which are semi-synthetic complexes of viral fragments made from free genetic material, are transported by virosomes. To distribute drugs, they have particular attachment to receptors and formation of membranes. virosomes are reconstructed virus coats in which the infectious nucleocapsid has been substituted with a powerful, non-infectious active pharmacological macromolecule for specific, focused activity. integrated substances like genes, antigens, or medication molecules that are mostly utilized in the production of vaccines. [5]

Structure / Design

Membrane proteins that are found in virosomes are either generated by recombinant technology or are obtained from the virus itself. In terms of their ultrastructureViral particles have a typical size of approximately 150 nanometre and are cylindrical, uniflagellar, reassembled viral vesicles. They are composed of viral spike proteins and membrane lipids on the surface, but they lack genetic material. virus containing peplomer extending through their membranes the virosome's exterior resembles an entire virus and Phospholipids, primarily phosphatidylcholine, are naturally occurring substances that make up the majority of virosomes. Phosphodiesterol alone is in charge of over 70% of the virosome's structure. Virosomes an essentially vacuous viruses' wrappers that have been reassembled. Because they lack genetic material, they cannot proliferate like the initial harmful infection. Hemagglutinin and a protein called (NA), A portion of a virosome unique properties they attributed in presence of an antibodies effective HA polypeptide encased in Clearly distinct from conventional proteoliposomal and liposomal delivery systems, the immunostimulatory qualities of virosomal particles are greatly enhanced by haemagglutinin glycoprotein, which also maintains the homogeneity and structural stability of virosomes. Essentially, HA is made up of two protein regions called HA1 and HA2, which are created when HA is translated into two subunits and remain connected by a chemical link. This this type of fusing process takes place between the viral and enzymatic membrane during influenza virus infection, ultimately leading to the discharge of DNA into desired cells' cytosol. Lacking the presence of a specific cell, HA is typically deactivated in an astringent environment approximately 5 pH and temperature 37°C, which ends its fusogenicity in an in vitro setting. [6]



Fig.1: Structure of virosome

History of virosome

Initial virosome formation occurred when the viruses that cause influenza, which carries neuraminidase and haemagglutinin membrane estimates, was moved from a virus's envelope the exterior filter or a coating on uniflagellar liposomes. This resulted in the formation of the virosome assembly. Proposals for a vaccination involving virosomes date back to the 1970s. The term "virosome" is suggested for this new organism because, upon closer inspection under an electron microscope, the resulting structure resembled a unique virus. [7]

MOA

The virosomes' outer covering is altered through the addition of the required proteins for fusion, but the center remains vacant. In uses involving medication delivery, that structure acts as a transport network this can move medications and antigenic in a certain way. The basic mechanism of virosome function is their unceasing capacity to unite. This conjugation capacity enables the transport of mixed or Antigens were encapsulated inside cells that present antigens using endocytosis through the receptors. Extensive immune responses also made possible by virosomes' efficiency in MHC class I or class II present in antigen routes. However, the capacity of antigenic vehicles to activate or excite helper lymphocytes such as T lymphocytes and destroy cells accounts for their advantage as supplements above immunizations. When viral particles attach to receptors in cell membranes made by forming Glycolipids or glycoproteins using ending sialic acids in their structures, discharge process begins. This process is carried out by hemagglutinin (HA). Virosomes then reach cells by enlargement caused by transporters.

Because of the internal environment, virosomes get stuck in endosomes and combine with other parts of the membrane that covers endosomal cells inside. Fusion activity is stimulated by hemaglutinin, a glycoprotein that is present on viral membranes (HA). The packed medications emerge from the virosome's phospholipid wrapping by the endosome during membrane-fusion, enabling the pharmaceuticals to pass through to the cell's plasma membrane. [8-12]



Fig. 2: Mechanism of action

Comparison of virosome and liposome

Many transport technologies can be utilized for delivering macromolecules to living organisms in vitro and in vivo; however, their efficacy in transporting enclosed molecules into the host cell's cytoplasm is not always guaranteed. Its capacity to establish a connection with the host cell explains this. currently as we understand, virosomes include the functional glycoproteins, which that give viruses their start. These glycoproteins have the ability to connect to receptors and fuse barriers, which allows for the best possible delivery of that particular material within the cytoplasm of the host cell. Studies comparing virosomes and liposomes from previous periods have shown as HVJ (Hemagglutinating virus of Japanese) viral particles have nearly three times the carrying capacity of cationic liposomes and can carry oligonucleotides intracellularly. The presence of HA, a crucial component of the the cold virosomal barrier, in virosomes is associated with reduced consistency, combination, legally binding, and structural stability through the host cell's endosome. This enhances HA-mediated cell fusion, whereby the virosomes are tightly bound inside the

endosome membrane and distributed within the organize cells cytoplasm through enhanced cytoplasmic transmission. Virosomal technology can be used to solve the issues Using liposomal structures, like the minimal pharmaceutical biomolecules' defence against outside microbial environments, such as acidic or alkaline PH within organelle. Due to their immunological qualities, virosomes have the ability to activate the host's immune system, which has the benefit of acting as a carrier and adjuvant for the introduction of antigens. Furthermore, the body's mononuclear lymphocyte network clears liposomes more quickly than it does viral particles. [13-17]

Advantages:

1.The FDA has cleared the use of virosomal gadgets in humans.

2. There is no risk of transmitting diseases while using the virosomal approach.

3. Drug control to avoid immorality or degeneration.

4. Virosomal technique is useful in many medications such as chemotherapeutic treatments, peptides, protein, genomes, prescription antibiotics, fungicides to .

5. There is no risk of anaphylaxis or autoimmunity.

6. Able to transfer medication into target cells' cytosol.

7. Encourages the endolysosomal pathway's merger action.

8. Target-specific antibodies dispersion and enhancement of the response of the immune system.

9. The body takes longer to absorb, transport, and excrete drugs.

10. Because the medication is enclosed, these methods have less adverse effects.

11. Fit for both old people and newborns.

12. Durable and high-quality immune system responses. [18 -22]

Disadvantages:

1. Issues with production.

2. There has little shelf life.

3. Because of an infectious protein on their outer layer, they might trigger humoral immune reactions.

4. One possible problem associated with virosomes is their short half-life dissolution inside the blood compartment.

5. There are no data on the long-term use of virosomes.

6. Absence of tests for quality control. [23-24]

PHARMACOKINETICS OF VIROSOMES

The differences between the impacts of the pharmacological of free and Medications trapped in liposomes in can translated using pharmacokinetics data, which can then be exploited for assessment design. In vivo preservation, dispersion, and degradation of virosomal carriers are regulated by pharmacokinetics.

The drug kinetics of viral particles necessitates the knowledge of probable attainable regions during intravascular construction because these are a widely appreciated method of collecting virosomal information utilized as medical use with the possible exception of cosmetic plans. Because virosomes are impacted by pharmacokinetics variables, they alter a medication's tissue distribution as well as its rate of absorption. In perfect circumstances, the drug was transported within the virosomal liquid phase during circulation and spilled at an amount sufficient to become observably accessible upon contact with tissue or other specific locations. When it comes to virosomal carriers, The quantity of free drugs that is known as bioavailability is able to escape the confines of the carrier and become readily available for redistribution to adjacent tissue. [25]

Administration of virosomes

In order to replicate physiological circumstances, produced viruses are frequently dissolved in saline buffer, which also include other additional compounds (e.g., sodium acetate, sodium lactate, potassium chloride, and calcium chloride). The number of viruses in their buffers typically vary from 20 to 200 mg mL–1, contingent on the specific objectives and characteristics of the virosome components. The prepared virosomes are often administered via pulmonary, topical in nature, in the muscle, intravenously, infusion, or edible routes after being sterilized (e.g., by membrane filtration). [26]

Methods of Preparation of Virosomes

1. Choice of Viruses Nucleocapsids from encapsulated viruses are removed to create virosomes, which are rebuilt viral membranes. The most popular way to make them is to modify the influenza virus.

But other viruses are also utilized to create virosomes, including the HIV virus, the Sendai virus,

the Herpes Simplex virus, the Semliki Forests virus, and the virus that causes Epstein the Sindhis virus, and the Friend of Mouse blood cancer virus.

2. Choosing the Target Compound (antibodies, Drug being used, or Macro molecules) Antigens are substances can be any kind of bacterial organism, cancer-causing cells, or even entire cells within their hosts. Genetic material, RNA, and vectors are examples of subcellular components that can be used as antigens and linked to the lipids anchor to aid in loaded processes of virosomes.

3. The membranes Reorganization Non-ionic Cleaners like Triton X 100, nondebt P-40, are used to solubilize the inactivated virus and precipitate the genetic material and internal viral proteins. A centrifuge method is applicable to extract nucleocapsids and virus's matrix proteins structures. Supernatant contains the phospholipids and a small number of proteins that are viral in origin. The purified viral envelope components are combined with additional endogenous lipids, such as cholesterol and phospholipids (phosphatidylcholine, sphingomyelin, phosphatidylethanolamine, and phosphates, for example). Prior to membrane reconstitution, cationic lipids such as DOTAP, DODAC, and stearylamine can be introduced to the surfaces to aid in amino acid binding and subsequent transport. In order to facilitate antigen binding, the payload—a medication or antigen attach to the lipids anchor is then homogenize using surface are suspended using a virosomes transport. Then, to encourage the development of virosome structures, the detergent is eliminated from the liquid that remains using techniques like dialysis and polar resins. It is possible to administer the manufactured virosomes parenterally, through the gastrointestinal tract, through the muscle, externally, or via inhalation means. They are also lyophilized-capable. Hydrophilic polymers including polyacryloylmorpholine, or poly(2-oxazoline) are introduced include the virosome membrane prolong the time they are in rotation. after complex distribution. [27-32]

Characterization of Virosomes

1. Protein Detection:- The production of virosomes typically yields a very consistent ratio of fat to protein. A technique called Sodium Dodecyl Sulphate Polyacrylamide Electrophoresis of gel is able verify whether the virosomes contain an Haemagglutinin (HA) protein.

2. Structure and Size: - The size and ultrastructure of virosomes must be determined using negative stain electron microscopy. It is preferable for the staining solutions to have a neutral pH in order to prevent acid-induced changes in the structure of haemagglutinin (HA).

3. Fusion Activity: Virosome typically exhibits the pH-dependent film combination movement similar to the negative influenza virus. When virosomal combination with organic or artificial target film is assessed utilising an excimer test in vitro. using pyrene-labeled lipids, a decreased in the excimer fluorescence a fusion activity is correlated with a decrease in the the depth of the surface of the pyrene-phosphatidylcholine label Employing an unorganised membrane in addition to. Additionally, it can be verified indirectly through measuring hemolytic action closely related to fusions actions or has pH dependent on the same as fusions. [33]

METHODS

Assay of Bradford's

The Bradford Proteins Test determines the protein concentration by adding the dye Coomassie to an aqueous sample. When protein attach with the Coomassie dye, the sample changes to brown into blue. The quantity of proteins in the sample can then be determined through determining the amount of blue using a spectrophotometer.

Dynamic light scattering (DLS)

It is a technique for tracking rapid changes in lasers intensity brought on by scattered particles or molecules into solutions; sizes as well as distribution can be computed. offers a quick and non-destructive method for determining the size of numerous biologics, such as peptides, proteins, viruses, and VLPs.

Electron scanning microscopy (SEM)

Using a beam of electrons travelling at energy level to concentrate and examine samples, the scanning electron microscope (SEM) is a type of electron microscope that scans the surface areas of microbes**.**

Transmission electron microscopy (TEM)

Transmission microscopy with electrons (TEM) makes it feasible to visualise the sizes, shapes, and positions of virus particles. TEM makes it possible to detect viral-like particles (VLPs) in mass collection. [34-37]

Evaluation test:

1. Vesicle shape or Surface morphology: - Freeze-break microscopy using electrons and transmission microscopy with electrons.

2. The surface charge: - Electrophoresis through stream-free.

3. Electrical surface potential or Surface pH: - Estimates of zeta potential and pH sensitive assays.

4. Drug discharge: Dialysis and diffusion cells.

5. Pyrogenicity: Limulus amoebocyte lysates (LAL) testing or rabbit temperature response testing

6. Animal poisonous quality: examining pathology, histology, and rates of survival. [38]

Application:

1. Gene therapy: In this scenario, the endosomal cell compartment's restricting barrier and the envelope of the virus fuse with the help of the Haemagglutinin membrane to facilitate a pH Low dependent fusion's reaction. The virus particles are then taken up by cell receptor endocytosis.

2. Cancer Treatment: Peptides that correlate to malignancy associated antigen (TAA), such as those from thyroid hormones-related proteins (PTH-rap) or reconstituted proteins likes her-2/neu, have also been introduced into the oncology field through virosomes. Fab, in conjunction with the anti-Fabdoxovirosome, merged the anti-proliferative characteristics of monoclonal antibodies with the in vivo doxorubicin lethal effect.

3.DNA/RNA: The synthesis of freshly initiated and const itutively conveyed proteins can be downregulated by small interfering RNA (siRNA) encased in virosomes, which can circumvent an absence of an appropriate transport system for these molecules. Nucleotides were delivered to the peritoneal cavity by administration of siRNA-loaded virosomes via the intraperitoneal route.

4.Malarial Therapy: -

a. A novel therapeutic delivery method for a variety of physiologically active compounds, including genetics, DNA, RNA, and other many applications, is represented by virosomes. It is possible to sufficiently alter the surface of virosomes to enable specific delivery of drugs. **b**. Such peptides regions that are act as a antigen for the malaria vaccine are NPNA region or AMA-1 merozoite region. Anti-malarial peptides included in the Virosome vaccine exhibit good immunological response and good tolerability in people.

c.immune Stimulations a pathogen-associated modularity patterns (PAMPs) are delivered to APC by virosomes. [39-40]

5.Targeted Drug Delivery Agents -Virosomes:

The efficient and timely distribution of a therapeutic substance to the intended place is a crucial need for any medication delivery system. Drugs must be altered and packaged such as therapeutically effective amounts of drug molecules reach the site of action in order to support targeted drug delivery. Drugs can be modified by changing their chemical or physical properties, which can lead to the synthesis of new compounds, by mixing the medication with other substances to change how it releases its ingredients in vivo, or by changing the physical structures of the drug molecules. In the end, these procedures require the participation of specific biological characteristics in order for the medicine to manifest its effects in the body. Conversely, the arrangement of molecules in appropriate. [41]

Optimization of virosomes

To extend the circulation period of virosomes during systemic distribution, Hydrophilic polymers [as well polyacryloylmorpholine, polyethylene glycol, and others] and polyvinylpyrrolidone, or poly(2-oxazoline)] can injected onto their envelopes. More significantly, targeting molecules (like antibodies) can be coupled to these Hydrophilic polymers and introduced into virosome membranes to produce a target selection capability. [42 -43]

FUTURE PROSPECTS

Virosomes are a new and effective medication delivery method that can transport a variety of biologically active compounds. However, the comprehensive pharmacological profiles and stability of virosomes should be studied thoroughly to verify their long-term reliability as a safe, efficient, and economical way of drug delivery. Moreover, the complicated assay processes for characterizing virosome products hold back the development of virosomes. Eff orts, therefore, need to be made in this respect to speed up the development of virosome-based products. In conclusion, biopharmaceuticals based on virosomes have a great chance of quickly making it into the clinic with additional research and development, particularly in the field of cancer treatment.

Conclusion

Virosomes represent a groundbreaking advancement in the field of drug delivery, offering a versatile and efficient platform for targeted therapeutic applications. Their unique combination of viral and non-viral properties enables the delivery of a wide range of therapeutic agents while ensuring biocompatibility and safety. The promising results observed in the delivery of antibodies, anticancer drugs, and vaccines highlight the potential of virosomes to enhance the efficacy of existing treatments and pave the way for innovative therapeutic strategies. Continued research and development in this area could lead to significant improvements in patient outcomes and the overall success of drug delivery systems.

Reference

1.andadapu G, Kolli P, Gopaiah KV, Teja R. Formulation and Evaluation of Econazole nitrMate Nano emulsion for Fungal Topical Use.

2.Kalra A, Sharma S. Virosomes: a viral envelope system having a promising application in vaccination and drug delivery system. Nanopharmaceutical Advanced Delivery Systems. 2021 Jan 12:145-60.

3.Felnerova D, Viret JF, Glück R, Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Current opinion in biotechnology. 2004 Dec 1;15(6):518-29.

4.Kalra N, Dhanya V, Saini V, Jeyabalan G. Virosomes: as a drug delivery carrier. American Journal of Advanced Drug Delivery. 2013;1(1):29-35.

5.Ali H, Akbar M, Iqbal B, Ali F, Sharma NK, Kumar N, Najmi A, Albratty M, Alhazmi HA, Madkhali OA, Zoghebi K. Virosome: An engineered virus for vaccine delivery. Saudi Pharmaceutical Journal. 2023 May 1;31(5):752-64.

6.Virosome: A vector in vaccine delivery Shubham Karpe1, Khushi Gupta1, Ganesh Vyas1, Princy Rana2, Fahad Khan3 and Rajesh Kumar1,

7.Liu, P., G. Chen, and J. Zhang, A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules, 2022. 27(4): p. 1372. [11]

8.Kapoor, B., et al., The Why, Where, Who, How, and What of the vesicular delivery systems. Advances in colloid and interface science, 2019. 271: p. 101985. [12]

9.Pattnaik, S., et al., Lipid vesicles: Potentials as drug delivery systems, in Nanoengineered Biomaterials for Advanced Drug Delivery. 2020, Elsevier. p. 163-180. [13]

10.Dong, W., et al., Monophosphoryl Lipid A-Adjuvanted Virosomes with Ni-Chelating Lipids for Attachment of Conserved Viral Proteins as Cross-Protective Influenza Vaccine. Biotechnology journal, 2018. 13(4): p. 1700645. [22]

11.Glück, R., C. Moser, and I.C. Metcalfe, Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert opinion on biological therapy, 2004. 4(7): p. 1139-1145. [23]

12.Sen, R., et al., A Review on Cubosome and Virosome: the novel drug delivery system. UJPSR, 2017. 3(1): p. 24-33 [26]

13.Chandra, S., et al., Site-specific phosphorylation of villin remodels the actin cytoskeleton to regulate Sendai viral glycoprotein-mediated membrane fusion. FEBS letters, 2019. 593(15): p. 1927-1943. [27]

14.Liu, H., et al., Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment. Acta pharmaceutica, 2015. 65(2): p. 105-116. [29]

15.Tamborrini, M., et al., Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models. NPJ vaccines, 2020. 5(1): p. 9. [30]

16.Cusi MG. Applications of influenza virosomes as a delivery system. Human vaccines. 2006 Jan 31;2(1):1-7.

17.Bhattacharya Sanjib, Muzumder Bhaskar. Virosomes A Novel Strategy for Drug Delivery and Targeting. Biopharm International, 2011; volume 2011 Supplement(issue1) [1]

18.Kalra Naresh, Dhanya V, Saini Vineeta, Dr.Jeyabalan G. Virosomes: As a Drug Delivery Carrier. American Journal of Advanced Drug Delivery, 2013; ISSN-2321-547X: 029-035 [4]

19.Sreeja C. Nair, SreelekshmiA. S,Krishanan K, Gopika G, Priyanka Nair T, et.al.Virosomes: A groundbreaking revolution in novel drug delivery. International Journal of Research in Pharmaceutical Sciences, 2020; Vol11(4): 3230. [5]

20.RathorePriyanka,Swami Gaurav. Virosomes:A Novel vaccination technology. International Journal of pharmaceutical sciences and research,2012; 3(8):3591-3597. [6]

21.Basavaraj K. Nanjwade, Ramchandra N. Chilkawar, Nagi F. Idris, TeerapolSrichana, et. al. Nanotechnology Based Virosomal Drug Delivery Systems. Journal of Nanotechnology and Ma terials Science,2014; 1(1):1-9. [7]

22.Dr. Shaikh Siraj N, Shahid Raza, Mohd. Aslam Ansari, Dr. G.J. Khan, Siddiqi Hifzurrahman MD Athar. Overview on virosomes as a novel carrier for drug delivery. Journal of Drug Delivery & Therapeutics, 2018; 8(6-s):429-434. [3]

23.Deshmukh R, Dewangan B, Harwansh RK, Agrawal R, Garg A, Chopra H. Current Trends in Nanotechnology-based Drug Delivery Systems for the Diagnosis and Treatment of Malaria: A Review. Current Drug Delivery. 2024.

24.Rajat S., Mohd Yasir; Virosomes: A Novel Carrier for Drug Delivery; International Journal of Pharm Tech Research;2010;2(4); 2327-2339

25.Virosome Virosome, a hybrid vehicle for effi cient and safe drug delivery and its emerging application in cancer treatment HANQING LIU 1, ZHIGANG TU 2*, FAN FENG2, HAIFENG SHI2, KEPING CHEN2, XIMING XU1

26.Singh, N., Gautam, S.P., Kumari, N., Kaur, R., Kaur, M., Virosomes as Novel drug delivery System: An Overview. PharmaTutor, 5, 47, 2017. [12]

27.Harandi, A.M., Medaglini, D., Shattock, R.J., Vaccine adjuvants: A priority for vaccine research. Vaccine, 28, 2363, 2010. [13]

28. Jabbal-Gill I. Nasal vaccine innovation. Journal of drug targeting. 2010 Dec 1;18(10):771-86.

29. Beg, S., Samad, A., Nazish, I., Sultana, R., Rahman, M., Zaki Ahmad, M., Akbar, M., Colloidal Drug Delivery Systems in Vaccine Delivery. Curr. Drug Targets, 14, 123, 2013. [15]

30. Kammer, A.R., Amacker, M., Rasi, S., Westerfeld, N., Gremion, C., Neuhaus, D., Zurbriggen, R., A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. Vaccine, 25, 7065, 2007.[16]

31.Amacker, M., Engler, O., Kammer, A.R., Vadrucci, S., Oberholzer, D., Cerny, A., Zurbriggen, R., Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int. Immunol., 17, 695, 2005. [2]

32. Narinder Singh, Surya Prakash Gautam, Neelam Kumari, Rupinder Kaur, Manpreet Kaur. Virosomes as Novel drug delivery System: An Overview. PharmaTutor, 2017; vol 5 (9): 47-55. [2]

33.Li, Y., Strategies for enhancing enzyme delivery using the heparin/protamine-based drug delivery system. 2003: University of Michigan. [63]

34.Kumar, V., et al., Preparation and characterization of nanocurcumin based hybrid virosomes as a drug delivery vehicle with enhanced anticancerous activity and reduced toxicity. Scientific reports, 2021. 11(1): p. 368. [60]

35.Homhuan, A., et al., Virosome and ISCOM vaccines against Newcastle disease: preparation, characterization and immunogenicity. European Journal of Pharmaceutical Sciences, 2004. 22(5): p. 459-468. [64]

36.de Jonge, J., et al., Use of a dialyzable short-chain phospholipid for efficient solubilization and reconstitution of influenza virus envelopes. Biochimica et biophysica acta (bba)-biomembranes, 2006. 1758(4): p. 527-536. [65]

37.Bhamare G.,Karpe M., Kadam V; virosome drug and vaccine delivery system;wjpps;2014;3(10);437-447 [9]

38.Patel S.S, Patel M.J, Patel N.M. Need, Development and application of Virosomal system in medicine. International Journal of Pharmaceutical Sciences and Nanotechnology 2010; 3(3):1065-1074

39.Cusi M.G. Applications of Influenza Virosomes as a Delivery System. Human Vaccines 2006; 2.1: 1-7. [13]

40.Virosomes-Hybrid Drug Delivery Systems Mustafeez Mujtaba Babar1, Najam-us-Sahar Sadaf Zaidi1, Alvina Gul Kazi1* and Abdul Rehman2

41. S. M. Moghimi and J. Szebeni, Stealth liposomes and lon g circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties, Prog. Lipid Res. 42 (2003) 463– 478.

42. E. Waelti, N. Wegmann, R. Schwaninger, A. We_ erwald, C. Wingenfeld, B. Rothen-Rutishauser and C. D. Gimmi, Targeting her-2/neu with antirat Neu virosomes for cancer therapy, Cancer Res. 62 (2002) 437–444

43.E. Mastroba_ ista, P. Schoen, J. Wilschut, D. J. Crommeli n and G. Storm, Targeting infl uenza virosomes to ovarian carcinoma cells, FEBS Le_. 509 (2001) 71–76.